The American College of Rheumatology recently launched Rheumatology for Primary Care, a new resource for primary care physicians (PCP) and advanced practice providers (APP) offering them expanded support and guidance to identify rheumatic diseases in their patients.
Dr. John Cush RheumNow
2 years 4 months ago
No Great Options for Treating VEXAS
For patients with the auto-inflammatory disease VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed.
https://t.co/tjCX1STnnD https://t.co/Bn40Nfxy9Y
Dr. John Cush RheumNow
2 years 4 months ago
The Window of Opportunity (5.24.2024)
Dr. Jack Cush reviews the journal reports and news from the past week on https://t.co/V10S4oVFsv. This week: blockbuster drugs, opioids in rheumatology and nontreatment of inflammatory arthritis?
https://t.co/zSjb2tKPWY
Dr. John Cush RheumNow
2 years 4 months ago
Preliminary results of ph IIB ORIGIN trial of placebo vs Atacicept (binds BAFF & APRIL)in 166 pts w/ IgA Nephropathy (Berger’s Dz) Gd-IgA1, hematuria, and UPCR (vs PBO) in the blinded 1st 36 weeks of the trial. https://t.co/tPhCrSaSTC https://t.co/6HqGFtb1IE
Dr. John Cush RheumNow
2 years 4 months ago
NHANES study of 2500 #RA pts, found a significant correlation between an inflammatory diet (meas by DII score) and inflammatory indices like systemic immune-inflamm Index (SII) & neutrophil-lymphocyte ratio (NLR) https://t.co/sWXZRrG6hV https://t.co/9IcLDF1Jlo
At the recent SPARTAN annual meeting in Cleveland, Dr. Jose Meade-Aguilar reported that amongst axial spondyloarthritis patients receiving nonsteroidal anti-inflammatory drugs, there was no difference in the risk for hypertension when comparing those on high vs. low dose NSAIDs.
Dr. John Cush RheumNow
2 years 4 months ago
Gangsin: 갱신 Korean: refresh, renew, updated
Over the last 20+ years, I have listened to patients confide their personal stories. Some remained paralyzed in their current state of distress, --I was one of them
https://t.co/Tr9w1XpWL0 https://t.co/E3kLnvfqOb
Nelly ZIADE 🍀 Nellziade
2 years 4 months ago
Untangling the relationship between smoking and systemic sclerosis: an analysis of the EUSTAR cohort
https://t.co/IB0cOAFnwl https://t.co/zpwm3JRKU4
Eric Topol EricTopol
2 years 4 months ago
The ability to predict hip fractures just went to a new level
https://t.co/k9cAPIJigd
A proteomic risk score was found to be strongly predictive of incident hip fractures in multiple independent populations
@NatureAging https://t.co/WZemPZqsev
Seminars in Arthritis and Rheumatism seminarthrheum
2 years 4 months ago
Available online, open access:
A review of CAR-T call therapy in rheumatic disease by @RyuOhno06
See below diagram of CAR-T therapy mechanism in cancer.
https://t.co/WALWulEDkW https://t.co/k1FD0zHtWu
CRA SCR CRASCRRheum
2 years 4 months ago
Congratulations to CRA member Dr. Andrew Chow, recipient of the Ontario Rheumatology Association's Rheumatologist of the Year Award! 🏆👏 https://t.co/2fB77VOBhv
Peter Nash drpnash
2 years 4 months ago
Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development https://t.co/DFdQy1Rn3D
CRA SCR CRASCRRheum
2 years 4 months ago
Congratulations to CRA member Dr. Lauren King, recipient of the Ontario Rheumatology Association's Early Career Rheumatology Award! 🏆👏 https://t.co/iM5MxzVaTg
Dr. John Cush RheumNow
2 years 4 months ago
Biomarkers Predictive of a Deucravacitinib Response in PsA
A phase II trial demonstrating the clinical efficacy of deucravacitinib, a TYK2 inhibitor, in PsA suggests specific biologic effects identified by biomarkers may predict clinical responses.
https://t.co/zsZl7JQydn https://t.co/4mGBYB4qU4
Dr. John Cush RheumNow
2 years 4 months ago
Lupus Research Alliance Grants for Lupus Innovation
The LRA) is proud to announce that nine international researchers are the recipients of this year’s Lupus Innovation Award (LIA).
https://t.co/v3S8u8aVvr https://t.co/Ve7OcIJT03
